Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 8/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | AKT1 | P31749 | 5/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13227806 | 0.91 | AKT1 (0.44) | HDAC1HDAC6HDAC8AKT1NOTUM | |
| SCHEMBL13227640 | 0.82 | NOTUM (0.51) | HDAC1HDAC6HDAC8NOTUMOPRM1 | |
| SCHEMBL4270092 | 0.81 | SLC18A3 (0.45) | HDAC1HDAC6HDAC8AKT1NOTUM | |
| SCHEMBL12847643 | 0.81 | NOTUM (0.42) | HDAC1HDAC6AKT1NOTUMHTR2A | |
| SCHEMBL12847767 | 0.81 | NOTUM (0.42) | HDAC1HDAC6AKT1NOTUMHTR2A | |
| SCHEMBL13227647 | 0.80 | HDAC1 (0.50) | HDAC1HDAC6HDAC8NOTUMSLC6A2 | |
| SCHEMBL13227641 | 0.80 | NOTUM (0.54) | HDAC1HDAC6HDAC8NOTUMSLC6A2 | |
| SCHEMBL4268737 | 0.79 | NOTUM (0.43) | HDAC1HDAC6HDAC8AKT1NOTUM | |
| SCHEMBL29644468 | 0.79 | NOTUM (0.43) | HDAC1HDAC6HDAC8AKT1NOTUM | |
| SCHEMBL13227637 | 0.78 | HDAC1 (0.52) | HDAC1HDAC6HDAC8NOTUMSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111805-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111805-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNB1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNY | HDAC1 230/4885HDAC6 508/4885HDAC8 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.